Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7
17 Octubre 2023 - 3:00PM
Business Wire
- Data from the A1 cohort of EDGE-Gastric, the Phase 2 study of
domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, in
first-line upper gastrointestinal cancers will be presented at the
virtual ASCO Monthly Plenary Series by Yelena Y. Janjigian, M.D.,
Chief Gastrointestinal Oncology, Memorial Sloan Kettering Cancer
Center on November 7, 2023
- Arcus Biosciences will also report third quarter 2023 results
and host a conference call aftermarket on November 7, 2023
Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data
from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be
presented at the American Society of Clinical Oncology (ASCO)
Monthly Plenary Series on November 7, 2023. EDGE-Gastric (also
known as ARC-21), a collaboration between Arcus and Gilead
Sciences, is a Phase 2 platform study evaluating various
combinations of domvanalimab, an Fc-silent anti-TIGIT monoclonal
antibody, and zimberelimab, an anti-PD-1 antibody, in patients with
locally advanced unresectable or metastatic gastric (G),
gastroesophageal junction (GEJ) or esophageal (E) adenocarcinoma.
Cohort A1 evaluates the combination of domvanalimab plus
zimberelimab and chemotherapy given as an initial treatment in
approximately 40 patients.
The ASCO Monthly Plenary Series is a virtual forum for
presentation and discussion of the latest cancer research.
According to ASCO, live presentations are accessible to virtual
attendees and available on-demand, and abstract presentations are
accompanied by a discussant presentation and followed by a live
Q&A session. Abstracts accepted for the Monthly Plenary Session
are also placed at the ASCO Annual Meeting in June 2024.
Title: EDGE-Gastric Arm A1: Phase 2
study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L)
advanced gastroesophageal cancer. Presenter: Yelena Y.
Janjigian, M.D., Chief, Gastrointestinal Oncology, Memorial Sloan
Kettering Cancer Center Date: Tuesday, November 7, 2023
Time: 12:00 p.m. – 1:00 p.m. PT / 3:00 p.m. – 4:00 p.m. ET
Webcast: The livestream presented by ASCO is free to
register on their website.
In addition, Arcus will release third quarter results and
pipeline updates after market close on November 7, 2023. Following
the release, Arcus management will host a conference call to
discuss the financial results, EDGE-Gastric results and other
pipeline updates.
Date: Tuesday, November 7, 2023
Time: 2:00 p.m. PT / 5:00 p.m. ET
Investors interested in listening to the conference call may do
so by dialing (646) 904-5544 (local) or (833) 470-1428 (toll-free),
using Conference ID: 258096. To access the live webcast and
accompanying slide presentation, please visit the “Investors &
Media” section of the Arcus Biosciences website at
www.arcusbio.com. A replay will be available following the live
event.
About EDGE-Gastric
The ongoing, multi-arm, global EDGE-Gastric trial (NCT05329766)
is evaluating the safety and efficacy of various combinations of
the Fc-silent anti-TIGIT antibody domvanalimab and the anti-PD-1
antibody zimberelimab in patients with locally advanced
unresectable or metastatic gastric (G), gastroesophageal junction
(GEJ) or esophageal (E) adenocarcinoma. Patients with previously
untreated G/GEJ/E adenocarcinoma received 1600 mg of domvanalimab
intravenously (IV) every four weeks (Q4w) plus 480 mg of
zimberelimab IV Q4W + FOLFOX (oxaliplatin 85 mg/m2 IV, leucovorin
400 mg/m2 IV, fluorouracil 400 mg/m2 IV bolus + 2400 mg/m2
continuous 46-48-hour IV infusion) every two weeks.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for people with cancer. In partnership with industry
partners, patients and physicians around the world, Arcus is
expediting the development of first- or best-in-class medicines
against well-characterized biological targets and pathways and
studying novel, biology-driven combinations that have the potential
to help people with cancer live longer. Founded in 2015, the
company has expedited the development of multiple investigational
medicines into clinical studies, including new combination
approaches that target TIGIT, PD-1, the adenosine axis (CD73 and
dual A2a/A2b receptor) and HIF-2a. For more information about Arcus
Biosciences’ clinical and pre-clinical programs, please visit
www.arcusbio.com or follow us on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231017188350/en/
Investor Inquiries: Pia Banerjee Head of Investor
Relations & Strategy (617) 459-2006 pbanerjee@arcusbio.com
Media Inquiries: Holli Kolkey VP of Corporate
Communications (650) 922-1269 hkolkey@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Arcus Biosciences (NYSE:RCUS)
Gráfica de Acción Histórica
De May 2023 a May 2024